Andreas Due Ørskov

5PUBLICATIONS
41CO-AUTHORS
HaematologyHaematological tumoursMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 21, 2025
A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 - Real-world outcomes and clinicopathological characteristics.

Johannes Frasez Soerensen, Daniel Tuyet Kristensen, Andreas Due Ørskov

|Jul 25, 2023
Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.

Daniel Tuyet Kristensen, Rasmus Froberg Brøndum, Andreas Due Ørskov

|Oct 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.

Casey L O'Connell, Maria R Baer, Andreas Due Ørskov

|Nov 10, 2020
Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers.

Sunil Kumar Saini, Andreas Due Ørskov, Anne-Mette Bjerregaard

|Apr 05, 2020
Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine.

Hitoshi Ohtani, Andreas D Ørskov, Alexandra S Helbo

Pageof 1

Frequent Collaborators

2 joint publications

Peter Jones

2 joint publications

Kirsten Grønbæk

2 joint publications

Staffan Holmberg-Thydén

2 joint publications

Daniel Tuyet Kristensen